OVOCA BIO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.006 EUR | 0.00% |
|
-7.69% | -40.00% |
| 2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 4.89M 4.59M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -4.69M | Net income 2022 | -5M -4.69M | EV / Sales 2021 | - |
| Net cash position 2021 | 6.59M 6.19M | Net cash position 2022 | 3.7M 3.48M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.23
x | P/E ratio 2022 |
-0.87
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.54% |
More Fundamentals
* Assessed data
More press releases
| 1 week | -7.69% | ||
| Current month | +20.00% | ||
| 1 month | +20.00% | ||
| 3 months | -40.00% | ||
| 6 months | -60.00% | ||
| Current year | -40.00% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.02
1 year
0.010.13
3 years
0.010.19
5 years
0.010.25
10 years
0.010.25
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.006 | 0.00% | 0 |
| 24-04-18 | 0.006 | -7.69% | 16,000 |
| 24-04-17 | 0.0065 | 0.00% | 0 |
| 24-04-16 | 0.0065 | 0.00% | 0 |
| 24-04-15 | 0.0065 | 0.00% | 0 |
Real-time Irish S.E., April 19, 2024 at 11:55 am EDT
More quotes
Ovoca Bio Plc is a biopharmaceutical company specialized in the development and manufacturing of peptides for the treatment of female sexual dysfunction.
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Calendar
2024-06-27
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -40.00% | 522K | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- OVXA Stock
